Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec

This article was originally published in The Pink Sheet Daily

Executive Summary

The threatened price cut is suspended until the court battle is played out between Novartis and the ministry, the Administrative Court ruled.

You may also be interested in...



Roche Hits A Wall With Its Tarceva Patent Claims In India; Novartis Moves Supreme Court For Glivec Rights

MUMBAI - For the two Swiss drug giants Novartis and Roche, there was much action at India's Supreme Court Aug. 28 as they separately continued the fight to safeguard patents on their life-saving oncology drugs steadfastly challenged by health activists and generic drug manufacturers alike in India

Facing Calls For Compulsory Licensing, Roche To Provide Fuzeon In Korea Under Compassionate Access Program

SEOUL - Nearly five years after refusing to supply its antiretroviral Fuzeon (enfuvirtide) to HIV/AIDS patients in South Korea due to pricing issues, Roche Korea says it will now provide the medication through its compassionate access program

South Korea Govt Proposes “Refund System” To Keep MNC Drug Prices Up, Provide Access To Patients

SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs is in pursuit of what it calls a "refunding system" under which multinational companies could sell their products at prices they want under the coverage of the local National Health Insurance System

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel